Risk of Myocarditis from COVID-19 Infection in People Under Age 20: A Population-Based Analysis
Myocarditis (or pericarditis or myopericarditis) from primary COVID19 infection occurred at a rate as high as 450 per million in young males. Young males infected with the virus are up 6 times more likely to develop myocarditis as those who have received the vaccine.
Painful muscles and joints, shortness of breath and lack of energy are all unwanted gifts of a disease that keeps on giving, say researchers. In addition, many victims suffer from post-traumatic stress disorder.
New: Remarkable 90% and durable protection (3 months) with booster vs Omicron vs hospital admission, the 1st US data, confirms + extends @UKHSA data👍https://t.co/5MgpcQp06Y pic.twitter.com/dkaJIma3H4— Eric Topol (@EricTopol) January 20, 2022
On Jan 6, 2022, the UK Government's Office of National Statistics (ONS) published their latest report on the prevalence of long COVID in the UK from a representative survey. As of Dec 6, 2021, around 1·266 million people living in the UK had self-reported long COVID (95% CI 1·228–1·304; 2% of the total population), defined as symptoms persisting for more than 4 weeks after the first confirmed or suspected COVID-19 infection. Of these individuals, 892 000 (70%) had confirmed or suspected COVID-19 at least 12 weeks previously.
Long COVID umfasst Symptome, die nach einer akuten COVID-19-Erkrankung neu auftreten und Wochen oder Monate nach Erkrankungsbeginn anhalten. Die Symptome können mit der Zeit abklingen oder sich zu einem anhaltenden Beschwerdebild entwickeln, das mit einer starken Einschränkung der Lebensqualität einhergeht. Eine Subgruppe von Menschen mit Long COVID hat eine große…
Frequency of Adverse Events in the Placebo Arms of COVID-19 Vaccine Trials
This systematic review and meta-analysis investigates the frequency of adverse events in placebo groups compared with that in vaccine groups in COVID-19 vaccine trials.
3/4 der Impfreaktionen/Nebenwirkungen eingebildet?Laut einer Untersuchung der Harvard Uni sind bis zu 76% der den Körper betreffenden Reaktionen nach Erst-Impfung und 52% der gemeldeten Folgen nach der 2. Impfdosis dem sogenannten „Nozebo“ (analog Plazebo) Effekt zuzuschreiben! pic.twitter.com/eoaKdIlxxu— OrthopaeDenker (@dokhollidays) January 20, 2022
Valneva: Positive Phase 3 Results for COVID-19 Vaccine
Valneva Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001 that successfully met both co-primary endpoints. Superio
The benefits, costs and feasibility of a low incidence COVID-19 strategy
In the summer of 2021, European governments removed most NPIs after experiencing prolonged second and third waves of the COVID-19 pandemic. Most count…
Omicron: A heavily mutated SARS-CoV-2 variant exhibits stronger binding to ACE2 and potently escape approved COVID-19 therapeutic antibodies
The new SARS-CoV-2 variant of concern “Omicron” was recently (Nov. 24th. 2021) spotted in South Africa and already spread around the world due to its enhanced transmissibility. The variant became conspicuous as it harbors more than thirty mutations in the spike protein with 15 mutations in the RBD region alone, potentially dampening the potency of therapeutic antibodies and enhancing the ACE2 binding. More worrying, Omicron infections have been reported in individuals who have received vaccines jabs in South Africa and Hong Kong. Here, we investigated the binding strength of Omicron with ACE2 and seven monoclonal antibodies that are either approved by FDA for COVID-19 therapy or undergoing phase III clinical trials. Computational mutagenesis and binding free energies could confirm that Omicron Spike binds ACE2 stronger than prototype SARS-CoV-2. Notably, three substitutions, i.e., T478K, Q493K, and Q498R, significantly contribute to the binding energies and doubled electrostatic potential of the RBDOmic-ACE2 complex. Instead of E484K substitution that helped neutralization escape of Beta, Gamma, and Mu variants, Omicron harbors E484A substitution. Together, T478K, Q493K, Q498R, and E484A substitutions contribute to a significant drop in the electrostatic potential energies between RBDOmic-mAbs, particularly in Etesevimab, Bamlanivimab, and CT-p59. CDR diversification could help regain the neutralization strength of these antibodies; however, we could not conduct this analysis to this end. Conclusively, our findings suggest that Omicron binds ACE2 with greater affinity, enhancing its infectivity and transmissibility. Mutations in the Spike are prudently devised by the virus that enhances the receptor binding and weakens the mAbs binding to escape the immune response. ### Competing Interest Statement The authors have declared no competing interest.
Ich danke allen, die sich dafür einsetzen, dass wir mehr über #LongCovid und #PostCovid erfahren!Auch wenn wir noch nicht genau wissen in welcher Häufigkeit mit #Langzeitfolgen zu rechnen ist:Wir müssen wohl auch bei Kindern von 2% ausgehen!https://t.co/1NvJgKodWo👇 pic.twitter.com/3ISRAEitTz— Amelie Thobaben (@AThobaben) August 17, 2021
Prophezeiungen, Prognosen, Vorhersagungen und Zukunftsgedanken der Querdenker ab September 2021 mit Bodo Schiffmann, Michael Ballweg, Attila Hildmann, ...
SARS-CoV-2 variants of concern and variants under investigation- Technical briefing 34 - technical-briefing-34-14-january-2022.pdf
This report has been published to share the detailed variant surveillance analyses which
contribute to the variant risk assessments and designation of new variants of concern (VOC)
and variants under investigation (VUI). This specialist technical briefing contains early data and
analysis on emerging variants and findings have a high level of uncertainty.
Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients tested between March 2020 and November 2021
Background: Long COVID is a post-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection syndrome characterised by not recovering for several weeks or months following the acute episode. The effectiveness of COVID-19 vaccines against long-term symptoms of COVID-19 is not well understood. We determined whether vaccination was associated with the incidence of reporting long-term symptoms post-SARS-CoV-2 infection Methods: We invited individuals who were PCR tested for SARS-CoV-2 infection at participating hospitals between March 2020-November 2021 to fill an online questionnaire that included baseline demographics, details of their acute episode and information about symptoms they were currently experiencing. Using binomial regression, we compared vaccinated individuals with those unvaccinated and those uninfected in terms of self-reported symptoms post-acute infection. Results: We included 951 infected and 2437 uninfected individuals. Of the infected, 637(67%) were vaccinated. The most commonly reported symptoms were; fatigue (22%), headache (20%), weakness (13%), and persistent muscle pain (10%). After adjusting for follow-up time and baseline symptoms, those who received two doses less likely than unvaccinated individuals to report any of these symptoms by 64%, 54%, 57%, and 68% respectively, (Risk ratios 0.36, 0.46, 0.43, 0.32, p
Patients who survive coronavirus disease 2019 (COVID-19) are at higher risk of post-acute sequelae involving pulmonary and several extrapulmonary organ systems—generally referred to as long COVID. However, a detailed assessment of kidney outcomes in long COVID is not yet available. Here we show that, beyond the acute phase of illness, 30-day survivors of COVID-19 exhibited higher risks of AKI, eGFR decline, ESKD, major adverse kidney events (MAKE), and steeper longitudinal decline in eGFR. The risks of kidney outcomes increased according to the severity of the acute infection (categorized by care setting into non-hospitalized, hospitalized, and admitted to intensive care). The findings provide insight into the long-term consequences of COVID-19 on kidney outcomes and suggest that post-acute COVID-19 care should include attention to kidney function and disease. Background COVID-19 is associated with increased risk of post-acute sequelae involving pulmonary and extrapulmonary organ systems—referred to as long COVID. However, a detailed assessment of kidney outcomes in long COVID is not yet available. Methods We built a cohort of 1,726,683 US Veterans identified from March 1, 2020 to March 15, 2021, including 89,216 patients who were 30-day survivors of COVID-19 and 1,637,467 non-infected controls. We examined risks of AKI, eGFR decline, ESKD, and major adverse kidney events (MAKE). MAKE was defined as eGFR decline ≥50%, ESKD, or all-cause mortality. We used inverse probability–weighted survival regression, adjusting for predefined demographic and health characteristics, and algorithmically selected high-dimensional covariates, including diagnoses, medications, and laboratory tests. Linear mixed models characterized intra-individual eGFR trajectory. Results Beyond the acute illness, 30-day survivors of COVID-19 exhibited a higher risk of AKI (aHR, 1.94; 95% CI, 1.86 to 2.04), eGFR decline ≥30% (aHR, 1.25; 95% CI, 1.14 to 1.37), eGFR decline ≥40% (aHR, 1.44; 95% CI, 1.37 to 1.51), eGFR decline ≥50% (aHR, 1.62; 95% CI, 1.51 to 1.74), ESKD (aHR, 2.96; 95% CI, 2.49 to 3.51), and MAKE (aHR, 1.66; 95% CI, 1.58 to 1.74). Increase in risks of post-acute kidney outcomes was graded according to the severity of the acute infection (whether patients were non-hospitalized, hospitalized, or admitted to intensive care). Compared with non-infected controls, 30-day survivors of COVID-19 exhibited excess eGFR decline (95% CI) of −3.26 (−3.58 to −2.94), −5.20 (−6.24 to −4.16), and −7.69 (−8.27 to −7.12) ml/min per 1.73 m2 per year, respectively, in non-hospitalized, hospitalized, and those admitted to intensive care during the acute phase of COVID-19 infection. Conclusions Patients who survived COVID-19 exhibited increased risk of kidney outcomes in the post-acute phase of the disease. Post-acute COVID-19 care should include attention to kidney disease.
Whoa—New study found active #SARSCoV2 in the intestines of children for up to 36 days—70% of infected children carried the active virus without showing any symptoms, giving worry to “invisible transmitters”. Of 22 cases, 20 were children under age of 6. 🧵https://t.co/r8cuyZECII pic.twitter.com/uaVc7MWSTJ— Eric Feigl-Ding (@DrEricDing) April 6, 2021
Four coronavirus (COVID-19) vaccines have now been approved for use in the UK. Rigorous
clinical trials have been undertaken to understand the immune response, safety profile and
efficacy of these vaccines as part of the regulatory process. Ongoing monitoring of the vaccines
as they are rolled out in the population is important to continually ensure that clinical and public
health guidance on the vaccination programme is built upon the best available evidence.
UK Health Security Agency (UKHSA), formerly Public Health England (PHE), works closely with
the Medicines and Healthcare Regulatory Agency (MHRA), NHS England, and other
government, devolved administration and academic partners to monitor the COVID-19
vaccination programme. Details of the vaccine surveillance strategy are set on the page
COVID-19: vaccine surveillance strategy (1). As with all vaccines, the safety of COVID-19
vaccines is continuously being monitored by the MHRA. They conclude that overall, the benefits
of COVID-19 vaccines outweigh any potential risks (2).
Comirnaty (BNT162b2) Erstversion 01/2021; zuletzt aktualisiert 12/2021 Ich werde als Ärztin immer wieder gefragt, ob ich etwas zu der Covid-19-Impfung sagen kann. Und zugegeben, als Assistenzärztin für Anästhesie (aktuell auf einer Intensivstation), bin ich zwar nicht unbedingt prädestiniert, über alle notwendigen Infos dieser Thematik zu verfügen, aber, nachdem ich schon vieles auf Social Media Kanälen lesen musste, habe ich versucht, die Fakten […]
Charité-Virologe Drosten im Interview: „Wie lange geht diese Quälerei noch weiter?“
Die Inzidenz ist hoch wie nie. Doch der Coronavirus-Experte Christian Drosten von der Charité Berlin macht Hoffnung: Das Änderungspotenzial von Sars-Cov-2 ist grundsätzlich begrenzt, sagt er.
Mild respiratory SARS-CoV-2 infection can cause multi-lineage cellular dysregulation and myelin loss in the brain
Survivors of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection frequently experience lingering neurological symptoms, including impairment in attention, concentration, speed of information processing and memory. This long-COVID cognitive syndrome shares many features with the syndrome of cancer therapy-related cognitive impairment (CRCI). Neuroinflammation, particularly microglial reactivity and consequent dysregulation of hippocampal neurogenesis and oligodendrocyte lineage cells, is central to CRCI. We hypothesized that similar cellular mechanisms may contribute to the persistent neurological symptoms associated with even mild SARS-CoV-2 respiratory infection. Here, we explored neuroinflammation caused by mild respiratory SARS-CoV-2 infection – without neuroinvasion - and effects on hippocampal neurogenesis and the oligodendroglial lineage. Using a mouse model of mild respiratory SARS-CoV-2 infection induced by intranasal SARS-CoV-2 delivery, we found white matter-selective microglial reactivity, a pattern observed in CRCI. Human brain tissue from 9 individuals with COVID-19 or SARS-CoV-2 infection exhibits the same pattern of prominent white matter-selective microglial reactivity. In mice, pro-inflammatory CSF cytokines/chemokines were elevated for at least 7-weeks post-infection; among the chemokines demonstrating persistent elevation is CCL11, which is associated with impairments in neurogenesis and cognitive function. Humans experiencing long-COVID with cognitive symptoms (48 subjects) similarly demonstrate elevated CCL11 levels compared to those with long-COVID who lack cognitive symptoms (15 subjects). Impaired hippocampal neurogenesis, decreased oligodendrocytes and myelin loss in subcortical white matter were evident at 1 week, and persisted until at least 7 weeks, following mild respiratory SARS-CoV-2 infection in mice. Taken together, the findings presented here illustrate striking similarities between neuropathophysiology after cancer therapy and after SARS-CoV-2 infection, and elucidate cellular deficits that may contribute to lasting neurological symptoms following even mild SARS-CoV-2 infection. ### Competing Interest Statement A.I. served as a consultant for Spring Discovery, Boehringer Ingelheim and Adaptive Biotechnologies. I.Y. reports being a member of the mRNA-1273 Study Group and has received funding to her institution to conduct clinical research from BioFire, MedImmune, Regeneron, PaxVax, Pfizer, GlaxoSmithKline, Merck, Novavax, Sanofi-Pasteur and Micron. M.M. serves in the scientific advisory board of Cygnal Therapeutics.
